Impact of Xuefu Zhuyu Capsules combined with conventional western medicine treatment on patients with angina pectoris
Objective To explore the effect of Xuefu Zhuyu Capsules combined with conventional western medicine treatment on patients with angina pectoris.Methods This study was a randomized controlled trial.A total of 100 patients with angina pectoris admitted to the Department of Cardiovascular Medicine,Sun Simmiao Hospital of Beijing University of Chinese Medicine from January 2022 to January 2024 were selected and were divided into a conventional group(50 cases)and a combined group(50 cases)according to the envelope drawing method.In the conventional group,there were 27 males and 23 females,aged(62.32±7.38)years,with a course of disease of(5.33±0.67)years,and the New York Heart Association(NYHA)cardiac function grade was grade Ⅰ in 32 patients and grade Ⅱ in 18 patients.In the combined group,there were 29 males and 21 females,aged(62.44±7.32)years,with a course of disease of(5.37±0.72)years,and the NYHA cardiac function grade was grade Ⅰ in 30 cases and grade Ⅱ in 20 cases.The conventional group was given conventional western medicine treatment:oral isosorbide mononitrate tablet 20 mg/time,metoprolol tartrate tablet 100 mg/time,twice a day;oral aspirin enteric-coated tablet 100 mg/time,atorvastatin calcium tablet 20 mg/time,once a day.The combined group was treated with Xuefu Zhuyu Capsules on the basis of the conventional group:6 capsules were taken orally each time,twice a day.Both groups were treated continuously for 2 months.The clinical indicators,cardiac function,Seattle Angina Questionnaire(SAQ)scores,and N-terminal pro B-type Natriuretic Peptide(NT-proBNP),creatine kinase isoenzyme(CK-MB),and soluble CD105(sCD105)levels were compared between the two groups before and after treatment,along with adverse reactions.x2 test and t test were used.Results Two months after treatment,the frequency of angina pectoris attack was(2.04±0.31)times/week in the combined group,the duration of angina pectoris was(1.35±0.21)min/time,the duration of shortness of breath was(1.64±0.32)d,the resting heart rate was(64.04±6.17)beats/min,the level of NT-proBNP was(135.41±22.70)U/L,the level of CK-MB was(52.33±5.46)ng/L,the level of sCD105 was(0.25±0.09)μg/L,which were lower than those in the conventional group[(3.51±0.48)times/week,(2.82±0.43)min/time,(3.03±0.55)d,(73.43±7.44)beats/min,(239.22±34.07)U/L,(66.41±6.77)ng/L,and(0.53±0.17)μg/L],with statistically significant differences(all P＜0.05).In the combined group,the left ventricular ejection fraction was(65.22±7.17)％,the cardiac output was(5.23±0.66)L/min,the stroke volume was(74.77±8.16)ml/time,the cardiac index was(3.11±0.65)L·min-1·m-2,which were higher than those in the conventional group[(57.41±6.25)％,(4.32±0.47)L/min,(65.65±7.29)ml/time,and(2.62±0.56)L·min-1·m-2],with statistically significant differences(all P＜0.05).The SAQ scores of the combined group were higher than those of the conventional group(all P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the conventional group and the combined group[8.0％(4/50)vs.10.0％(5/50)](x2=0.122,P=0.727).Conclusions On the basis of conventional western medical treatment,combining Xuefu Zhuyu Capsules can significantly improve clinical indicators,cardiac function,SAQ score,and levels of NT-proBNP,CK-MB,and sCD105 in patients with angina pectoris.The safety profile is good,and it is recommended for widespread application.
万方数据
维普
